New 'Living Drug' trial targets Tough-to-Treat blood cancer
NCT ID NCT06871410
Summary
This early-stage trial is testing the safety and best dose of a new cell therapy called CD83 CAR T for adults with acute myeloid leukemia (AML) that has returned or not responded to prior treatments. Doctors will collect a patient's own immune cells, genetically modify them to target a protein found on leukemia cells, and infuse them back. The main goal is to see if this approach is safe and tolerable while looking for early signs it can fight the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.